Laurus Labs Ltd (LAURUSLABS) Q1 FY27 Results Analysis: EBITDA Margin Expands 715 bps, Revenue Grows 29%
Laurus Labs Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,026.31 Cr (+29.10% YoY) and PAT growth of +125.49% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 24, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 2,026.31 Cr (+29.10% YoY) |
| PAT (Q1) | Rs. 367.60 Cr (+125.49% YoY) |
| EBITDA margin | 31.50% (+715 bps YoY) |
| EPS (Q1) | Rs. 6.81 (+125.50% YoY) |
| Market cap | Rs. 86,504.76 Cr |
| CMP | Rs. 1,601.20 |
Quarter Snapshot
Laurus Labs delivered a strong Q1 with 29% revenue growth, 715 bps EBITDA margin expansion to 31.5%, and PAT more than doubling. Subsidiary profitability surged, and regulatory risk is mitigated by a zero-observation EIR. However, the absence of management guidance and segment-level disclosure limits visibility into the sustainability of the CDMO and ARV trends.
Key Investment Insights
Key Positives
- Revenue grew 29.1% YoY to Rs.2,026.31 Cr, with sequential acceleration to 11.9% QoQ.
- EBITDA margin expanded 715 bps YoY to 31.50%, with every cost head improving as a percentage of revenue.
- PAT attributable to equity holders rose 125.5% YoY to Rs.367.60 Cr, and EPS doubled to Rs.6.81.
- Subsidiary PAT contribution surged from Rs.5.08 Cr to Rs.77.64 Cr, indicating strong profitability in regulated generics or Laurus Bio.
- Finance costs fell 18% YoY despite slight QoQ increase, suggesting debt reduction or lower rates.
- Clean audit opinion with no exceptional items or qualifications.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.